Publications
88
Citations
2,690
Est. group size
—
Recurring co-author estimate
Active years
20
Publishing since 2007
Julie K. Bower's work centers on real-world outcomes research in chronic disease management, including studies on insulin use behaviors among people with diabetes and healthcare providers, long-term registry-based safety and effectiveness studies of cystic fibrosis therapies, and cardiovascular risk factor analysis using large national health survey datasets. The research relies heavily on survey methods, patient registries, and secondary data analysis of population health databases to understand patient and provider behavior and treatment outcomes.
Publication output was higher earlier in the decade (around 2017-2020) and has declined to a lower, fairly steady pace of a few publications per year in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Understanding suboptimal insulin use in type 1 and type 2 diabetes
DiRROS repository (University of Maribor) · 2026
- Understanding Suboptimal Insulin Use in Type 1 and Type 2 Diabetes: A Cross-Sectional Survey of People with Diabetes
Patient Preference and Adherence · 2025
- Socio-demographic differences in the dietary inflammatory index from National Health and Nutrition Examination Survey 2005–2018: a comparison of multiple imputation versus complete case analysis
Public Health Nutrition · 2024
- Understanding suboptimal insulin use in type 1 and 2 diabetes: a cross-sectional survey of healthcare providers who treat people with diabetes
BMC Primary Care · 2024
- WS01.04 Real-world outcomes in people with cystic fibrosis (pwCF) treated with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) with up to three years of follow-up
Journal of Cystic Fibrosis · 2024
- Survival After MI in a Community Cohort Study: Contribution of Comorbidities in NSTEMI
UNC Libraries · 2024
- Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study
Journal of Cystic Fibrosis · 2023
- Differences in Patient’s Behaviors and Endocrinologist Perceptions of Missed Bolus Insulin Doses in the United States
Metabolism · 2023
- WS16.03 Registry-based study of people with cystic fibrosis (pwCF) treated with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA): Up to 2 years of real-world outcome data
Journal of Cystic Fibrosis · 2023
- 807-P: Patient and Health Care Provider Experiences of Suboptimal Insulin Dosing in the United States
Diabetes · 2023
- Understanding Suboptimal Insulin Use in Type 1 and 2 Diabetes: A Cross-sectional Survey of Healthcare Providers who Treat People With Diabetes
Research Square · 2023
- Varieties of capitalism, competition policy and the UK alcoholic beverages industry
2022
- Ten-year cardiovascular risk among cancer survivors: The National Health and Nutrition Examination Survey
PLoS ONE · 2021
- Acute and Chronic Effects of Clothianidin, Thiamethoxam and Methomyl on Chironomus dilutus
Bulletin of Environmental Contamination and Toxicology · 2021
- Real-world effects of tezacaftor/ivacaftor (TEZ/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data
2021
- Circulation×8
- Journal of Cystic Fibrosis×4
- Research Square×4
- PLoS ONE×3
- Annals of Epidemiology×3
- Joshua J. Joseph
Medicine · The Ohio State University
- Nilay S. Shah
Medicine · The Ohio State University
- Xiaoning Huang
Medicine · The Ohio State University
- Lucia C. Petito
Medicine · The Ohio State University
- Sadiya S. Khan
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile